In summary, this study found that BTN3A1 expression was increased in SLE patients, and BTN3A1 inhibited the IL‐38‐ferroptosis axis, and then, promoted inflammation and induced lupus‐like disease. Here, IL1F10 is linked to systemic lupus erythematosus.